
The study analyzed the impact of the 2018 CARMENA trial on cytoreductive nephrectomy practices in the USA using data from the National Cancer Database (2004-2020). Results showed a statistically significant 31.8% relative reduction in CN rates among metastatic clear cell renal cell carcinoma patients post-2018, with actual rates dropping from 34.7% to 21.9%. The change suggests a broad shift in clinical practice following the CARMENA trial, though additional untested factors may have contributed. The study underscores how pivotal trials can influence treatment decisions nationwide.
Like
Save
Share